Treatment choice in EGFR-mutant non-small-cell lung cancer

被引：6
|
作者：
Brueckl, Wolfgang M. [1 ]
机构：
[1] Paracelsus Med Univ, Gen Hosp Nuernberg, Dept Resp Med Allergol & Sleep Med, D-90419 Nurnberg, Germany
来源：
LANCET ONCOLOGY | 2017年 / 18卷 / 11期
关键词：
SURVIVAL-DATA; AFATINIB; TRIAL; GEFITINIB;
D O I：
10.1016/S1470-2045(17)30684-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1425 / 1426
页数：3
相关论文
共 50 条
  • [31] Spatiotemporal T790M Heterogeneity in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer
    Hata, Akito
    Masago, Katsuhiro
    Katakami, Nobuyuki
    Imai, Yukihiro
    Yatabe, Yasushi
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (08) : E64 - E65
  • [32] Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
    Jin, Rui
    Zhao, Jing
    Xia, Lexin
    Li, Qin
    Li, Wen
    Peng, Ling
    Xia, Yang
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [33] Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
    Zhu, Viola W.
    Klempner, Samuel J.
    Ou, Sai-Hong Ignatius
    [J]. TRENDS IN CANCER, 2019, 5 (11): : 677 - 692
  • [34] Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
    Nishima, Shunichi
    Miyanaga, Akihiko
    Saito, Sho
    Yuasa, Mizuki
    Takahashi, Satoshi
    Kashiwada, Takeru
    Sugano, Teppei
    Noro, Rintaro
    Minegishi, Yuji
    Terasaki, Yasuhiro
    Saito, Yoshinobu
    Kubota, Kaoru
    Seike, Masahiro
    Gemma, Akihiko
    [J]. INTERNAL MEDICINE, 2021, 60 (04) : 591 - 594
  • [35] Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
    Zhang, Shi-Ling
    Zhang, Chan -Yuan
    Chen, Yu-Qing
    Li, Yu -Fa
    Xie, Zhi
    Zhang, Xu-Chao
    Zhou, Qing
    Zhong, Wen-Zhao
    Huang, Jie
    Sun, Hao
    Zheng, Ming-Ying
    Xiao, Fa-Man
    Yan, Hong-Hong
    Lu, Dan-Xia
    Lv, Zhi-Yi
    Wu, Yi-Long
    Chen, Hua-Jun
    Yang, Jin-Ji
    [J]. JOURNAL OF THORACIC DISEASE, 2023, 15 (09) : 4620 - 4635
  • [36] A differential analysis of TCR repertoire between patients with EGFR-mutant and KRAS-mutant non-small-cell lung cancer
    Xie, Yuancai
    Li, Yingmei
    Dong, Linfeng
    Chen, Shifu
    Liu, Jixian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
    Nguyen, Kim-Son H.
    Neal, Joel W.
    [J]. BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 337 - 345
  • [38] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
    Naito, Yoichi
    Goto, Koichi
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040
  • [39] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [40] Patritumab Deruxtecan Is Efficacious in EGFR-Mutant Non-Small Cell Lung Cancer
    Zhang, H.
    Yu, X.
    Ye, J.
    Li, H.
    Hu, J.
    Tan, Y.
    [J]. CANCER DISCOVERY, 2023, 13 (12) : 2501 - 2501
12345